JP2018512047A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512047A5
JP2018512047A5 JP2017557481A JP2017557481A JP2018512047A5 JP 2018512047 A5 JP2018512047 A5 JP 2018512047A5 JP 2017557481 A JP2017557481 A JP 2017557481A JP 2017557481 A JP2017557481 A JP 2017557481A JP 2018512047 A5 JP2018512047 A5 JP 2018512047A5
Authority
JP
Japan
Prior art keywords
cell
cells
tcr
modified
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017557481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512047A (ja
JP6899333B2 (ja
Filing date
Publication date
Priority claimed from GBGB1501175.2A external-priority patent/GB201501175D0/en
Application filed filed Critical
Publication of JP2018512047A publication Critical patent/JP2018512047A/ja
Publication of JP2018512047A5 publication Critical patent/JP2018512047A5/ja
Application granted granted Critical
Publication of JP6899333B2 publication Critical patent/JP6899333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017557481A 2015-01-23 2016-01-22 汎用キラーt細胞 Active JP6899333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
GB1501175.2 2015-01-23
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (3)

Publication Number Publication Date
JP2018512047A JP2018512047A (ja) 2018-05-10
JP2018512047A5 true JP2018512047A5 (https=) 2019-03-07
JP6899333B2 JP6899333B2 (ja) 2021-07-07

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557481A Active JP6899333B2 (ja) 2015-01-23 2016-01-22 汎用キラーt細胞

Country Status (17)

Country Link
US (2) US11155786B2 (https=)
EP (3) EP4681735A3 (https=)
JP (1) JP6899333B2 (https=)
KR (1) KR102479118B1 (https=)
CN (1) CN107250351A (https=)
AU (2) AU2016208475B2 (https=)
CA (1) CA2973924C (https=)
DK (1) DK3247791T3 (https=)
EA (1) EA201791381A1 (https=)
ES (1) ES2922231T3 (https=)
GB (1) GB201501175D0 (https=)
IL (1) IL253464B (https=)
MX (1) MX390756B (https=)
PL (1) PL3247791T3 (https=)
PT (1) PT3247791T (https=)
SG (1) SG11201705693XA (https=)
WO (1) WO2016116601A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
US20190134095A1 (en) * 2016-05-02 2019-05-09 Cerus Corporation Compositions and methods for improved nk cell therapies
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
WO2018129199A1 (en) 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CA3110946A1 (en) * 2018-08-31 2020-03-05 Invectys SA Method to assess car functionality
EP3941490A4 (en) * 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELLULAR THERAPY
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CA3148127A1 (en) 2019-07-29 2021-02-04 Massachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
MX2023003372A (es) 2020-09-24 2023-05-04 Medigene Immunotherapies Gmbh Nuevos receptores prame y usos de los mismos.
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
CN118215498A (zh) 2021-09-21 2024-06-18 奥斯陆大学医院Hf 末端脱氧核苷酸转移酶(TdT)的结合蛋白
TW202325844A (zh) * 2021-11-03 2023-07-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
US20260021183A1 (en) * 2022-07-22 2026-01-22 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
WO2024261045A1 (en) 2023-06-20 2024-12-26 Zelluna Immunotherapy As Methods of enhancing or modifying nk cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
ATE323756T1 (de) 1997-04-30 2006-05-15 Hans Klingemann Natürliche killerzelllinien und verfahren zu ihrer verwendung
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
WO2003048337A2 (en) 2001-12-04 2003-06-12 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
AU2005277831B2 (en) 2004-07-10 2012-11-22 The Institute For Cancer Research Genetically modified human natural killer cell lines
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
DK2817620T3 (en) * 2012-02-22 2016-09-05 Verik Bio Inc IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION
WO2014037422A1 (en) 2012-09-04 2014-03-13 Inven2 As Selective and controlled expansion of educated nk cells
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CA2900380A1 (en) 2013-02-04 2014-08-07 Roger Williams Medical Center Methods and compositions for treating gastrointestinal stromal tumor(gist)
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法
ES2806776T3 (es) 2014-06-18 2021-02-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Células NK-92 que expresan CAR como agentes terapéuticos celulares
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Similar Documents

Publication Publication Date Title
JP2018512047A5 (https=)
Forostyak et al. The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
Lohmueller et al. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
CN110177558B (zh) 用于病毒特异性t细胞的活化和扩增的平台
JP2016501013A5 (https=)
JP2021176866A (ja) 共通ネオ抗原
WO2020021045A3 (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
WO2013120012A3 (en) Cdim binding proteins and uses thereof
JP2018512161A5 (https=)
JP2018500006A5 (https=)
JP2019504892A5 (https=)
FI3102609T3 (fi) Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi
JP2016539929A5 (https=)
EP4545639A3 (en) Engineered gamma delta t-cells
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
JP2013537426A5 (https=)
JP2018531016A5 (https=)
Zhu et al. Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia
JP2014515258A5 (https=)
Court et al. Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells
JP2022513164A5 (https=)
Zhao et al. Immunotherapy: A new target for cancer cure
JP2016528176A5 (https=)